Advertisement
Advertisement
U.S. Markets open in 4 hrs 27 mins
Advertisement
Advertisement
Advertisement
Advertisement

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9594+0.0024 (+0.25%)
At close: 04:00PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference

    SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces that Kyle Guse, Chief Financial Officer and General Counsel, will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference. The conference is be

  • Simply Wall St.

    Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

    SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended March 31, 2022, and provides an update on recent company developments. Key developments from Q1 2022 and to date include: Received issuance of key U.S. patent covering End

Advertisement
Advertisement